Semler Scientific, a prominent player in the medical device sector, has made headlines with its recent investment of $50 million in Bitcoin. This strategic move, undertaken between May 13 and May 22, significantly enhances the company’s cryptocurrency portfolio, increasing its total Bitcoin holdings to an impressive $474.4 million. This positions Semler within the top 13 companies globally holding Bitcoin, which is becoming an increasingly popular asset among corporate treasuries.
According to a disclosure on May 23, Semler acquired a total of 455 BTC at an average price of $109,801 per coin. The funds for this purchase were sourced from an at-the-market stock offering program, which has allowed the company to raise approximately $115 million by selling roughly 3 million shares of common stock.
Despite this bold investment, Semler Scientific’s stock experienced a slight decrease of 1.36% on the same day the news broke. This dip aligns closely with the overall performance of the Nasdaq, which was down 1%, reflecting broader market trends rather than negative sentiment towards the company’s Bitcoin strategy.
In its Q1 2025 earnings report released on May 13, Semler revealed a concerning 44% drop in revenue year-over-year. Nonetheless, the company remains optimistic about its Bitcoin treasury strategy, which has so far led to an 18% decline in its shares throughout 2025, per Google Finance data.
As interest in Bitcoin treasury companies grows, investors are increasingly looking for ways to gain exposure to the value fluctuations of Bitcoin. Semler’s approach mirrors that of other companies, such as Michael Saylor’s strategy initiated in August 2020, which has seen Bitcoin yield a remarkable 181.6% increase year-to-date. Notably, Semler Scientific shares have witnessed a 53% rise since the announcement of their Bitcoin acquisition strategy in May 2024.
As the landscape of corporate investment continues to evolve, the actions taken by Semler Scientific signal a compelling trend that may inspire other companies within and beyond the medical sector to explore similar paths.
